TY  - JOUR
A1  - Tockhorn, Philipp
A1  - Sutter, Johannes
A1  - Cruz Bournazou, Alexandros
A1  - Wagner, Philipp
A1  - Jäger, Klaus
A1  - Yoo, Danbi
A1  - Lang, Felix
A1  - Grischek, Max
A1  - Li, Bor
A1  - Li, Jinzhao
A1  - Shargaieva, Oleksandra
A1  - Unger, Eva
A1  - Al-Ashouri, Amran
A1  - Köhnen, Eike
A1  - Stolterfoht, Martin
A1  - Neher, Dieter
A1  - Schlatmann, Rutger
A1  - Rech, Bernd
A1  - Stannowski, Bernd
A1  - Albrecht, Steve
A1  - Becker, Christiane
T1  - Nano-optical designs for high-efficiency monolithic perovskite-silicon tandem solar cells
JF  - Nature nanotechnology
N2  - Designing gentle sinusoidal nanotextures enables the realization of high-efficiency perovskite-silicon solar cells <br /> Perovskite-silicon tandem solar cells offer the possibility of overcoming the power conversion efficiency limit of conventional silicon solar cells. Various textured tandem devices have been presented aiming at improved optical performance, but optimizing film growth on surface-textured wafers remains challenging. Here we present perovskite-silicon tandem solar cells with periodic nanotextures that offer various advantages without compromising the material quality of solution-processed perovskite layers. We show a reduction in reflection losses in comparison to planar tandems, with the new devices being less sensitive to deviations from optimum layer thicknesses. The nanotextures also enable a greatly increased fabrication yield from 50% to 95%. Moreover, the open-circuit voltage is improved by 15 mV due to the enhanced optoelectronic properties of the perovskite top cell. Our optically advanced rear reflector with a dielectric buffer layer results in reduced parasitic absorption at near-infrared wavelengths. As a result, we demonstrate a certified power conversion efficiency of 29.80%.
Y1  - 2022
U6  - https://doi.org/10.1038/s41565-022-01228-8
SN  - 1748-3387
SN  - 1748-3395
VL  - 17
IS  - 11
SP  - 1214
EP  - 1221
PB  - Nature Publishing Group
CY  - London [u.a.]
ER  - 
TY  - JOUR
A1  - Peter, Lena
A1  - Wendering, Désirée Jacqueline
A1  - Schlickeiser, Stephan
A1  - Hoffmann, Henrike
A1  - Noster, Rebecca
A1  - Wagner, Dimitrios Laurin
A1  - Zarrinrad, Ghazaleh
A1  - Münch, Sandra
A1  - Picht, Samira
A1  - Schulenberg, Sarah
A1  - Moradian, Hanieh
A1  - Mashreghi, Mir-Farzin
A1  - Klein, Oliver
A1  - Gossen, Manfred
A1  - Roch, Toralf
A1  - Babel, Nina
A1  - Reinke, Petra
A1  - Volk, Hans-Dieter
A1  - Amini, Leila
A1  - Schmueck-Henneresse, Michael
T1  - Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients
JF  - Molecular therapy methods and clinical development
N2  - Solid organ transplant (SOT) recipients receive therapeutic immunosuppression that compromises their immune response to infections and vaccines. For this reason, SOT patients have a high risk of developing severe coronavirus disease 2019 (COVID-19) and an increased risk of death from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Moreover, the efficiency of immunotherapies and vaccines is reduced due to the constant immunosuppression in this patient group. Here, we propose adoptive transfer of SARS-CoV-2-specific T cells made resistant to a common immunosuppressant, tacrolimus, for optimized performance in the immunosuppressed patient. Using a ribonucleoprotein approach of CRISPR-Cas9 technology, we have generated tacrolimus-resistant SARS-CoV-2-specific T cell products from convalescent donors and demonstrate their specificity and function through characterizations at the single-cell level, including flow cytometry, single-cell RNA (scRNA) Cellular Indexing of Transcriptomes and Epitopes (CITE), and T cell receptor (TCR) sequencing analyses. Based on the promising results, we aim for clinical validation of this approach in transplant recipients. Additionally, we propose a combinatory approach with tacrolimus, to prevent an overshooting immune response manifested as bystander T cell activation in the setting of severe COVID-19 immunopathology, and tacrolimus-resistant SARS-CoV-2-specific T cell products, allowing for efficient clearance of viral infection. Our strategy has the potential to prevent severe COVID-19 courses in SOT or autoimmunity settings and to prevent immunopathology while providing viral clearance in severe non-transplant COVID-19 cases.
Y1  - 2022
U6  - https://doi.org/10.1016/j.omtm.2022.02.012
SN  - 2329-0501
VL  - 25
SP  - 52
EP  - 73
PB  - Cell Press
CY  - Cambridge
ER  -